RxDoctor Payments Data

Sunanda Kane, MD

Gastroenterology · Rochester, MNNPI 1801957634

Payments from drug & device makers

$35,202in general payments, 2019–2025

Across 27 payments — averaging $1303.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$13K
  • Johnson & Johnson$5K
  • Fresenius Kabi USA, LLC$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Boehringer Ingelheim$3K
  • Gilead$3K
  • plus $4K from 6 others

What the payments were for

  • Consulting fees$19,87588%
  • Speaking & faculty fees$2,23110%
  • Food & beverage$3412%
  • Education$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.1$12,500
Johnson & Johnson5$5,415
Fresenius Kabi USA, LLC2$3,660
Takeda Pharmaceuticals U.S.A., Inc.9$3,392
Boehringer Ingelheim1$3,250
Gilead1$2,990
Samsung Bioepis Co., Ltd.1$2,250
Techlab, Inc.1$1,200
Biogen3$450
AstraZeneca1$68
AbbVie1$14
Ironwood Pharmaceuticals, Inc1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,202 in reported general payments places this provider in the 80th percentile of 365 gastroenterology providers in Minnesota.

See all gastroenterology providers in Minnesota

Medicare billing

Part B allowed, 2024
$21,485
Medicare patients
159
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab79$2,054,253
GattexTeduglutide12$557,246
Humira PenAdalimumab23$214,682
Humira(Cf) PenAdalimumab13$86,569
Cromolyn Sodium11$9,216
Vancomycin Hcl23$4,392
Mesalamine14$4,252
LoperamideLoperamide Hcl41$1,364
Azathioprine19$951
CholestyramineCholestyramine (With Sugar)13$774
Ciprofloxacin Hcl14$306
Sulfasalazine11$292
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl14$258
Omeprazole11$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$5,415$2,054,25379 claims
Takeda Pharmaceuticals U.S.A., Inc.Gattex$3,392$557,24612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 gastroenterology providers in Minnesota.

Other gastroenterology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →